Major Depressive Disorder Clinical Trial
Official title:
Naturalistic Pilot Study Comparing the Feasibility of Applying a Student Senior Isolation Prevention Partnership vs. Problem-solving Therapy vs. Waitlist Control in Patients Suffering From Late-life Depression During the COVID-19 Pandemic: A Randomized Controlled Trial
The COVID-19 pandemic and continued lockdown measures have led to social isolation that is likely disproportionately affecting community-dwelling seniors. This social isolation of seniors is expected to cause detrimental health effects especially in those who have an ongoing or new onset late life depressive episode. The COVID-19 pandemic has also made accessing formal psychotherapy services increasingly difficult due to an increased demand for these services and a limited number of trained professionals available to deliver these interventions. We plan to conduct an open label, pilot, randomized controlled trial (RCT), comparing a virtually delivered (telephone) student led mental health supportive initiative, Student Senior Isolation Prevention Partnership (SSIPP) (n=15) compared to a telephone delivered standard psychotherapy intervention, problem-solving therapy (PST) (n=15) versus a wait list control (n=15) in community-dwelling seniors suffering from late life depression. Participants in this study will be blinded to the hypothesis, while those performing data analysis will be blinded to treatment allocation. Both SSIPP and PST will be delivered via telephone as a weekly session for 12-weeks. Feasibility measures of recruitment, retention and costs will be collected as primary outcome measures. Self-rated measures of depression, anxiety, isolation and resilience will comprise secondary exploratory outcomes. We anticipate that it will be feasible to conduct an RCT of these telephone interventions, SSIPP and PST, in socially isolated community-dwelling seniors. Data from this study will be critical to plan a subsequent confirmatory large-scale RCT. It could be that telephone delivered medical student led supportive intervention, SSIPP and/or a telephone delivered psychotherapy initiative, PST, can be feasibly applied in the current pandemic to a high-risk population, isolated seniors suffering from depression.
BACKGROUND The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the current coronavirus disease 2019 (COVID-19) outbreak, has led to strict social distancing and social isolation recommendations from the World Health Organization (1). As the elderly are most susceptible to critical illness and fatality due to infection with SARS-CoV-2, they have also been subjected to the most stringent social isolation guidelines in Canada as an attempt to prevent death in this population (1,2). While these public health measures are necessary to prevent the spread of SARS-CoV-2 among our vulnerable geriatric populations and to protect our over-burdened healthcare systems, social isolation has had a detrimental impact on the mental health of this population and has been deemed a mental health crisis (1,3). The aim of this study is to assess the feasibility of delivering SSIPP in London, Canada, as compared to an active control, PST, as well as a wait list control. Such a study would also allow to collect effect size estimates on the efficacy of SSIPP on self-rated depression, anxiety, isolation and resilience among community-dwelling seniors. As SSIPP is more accessible and more readily available than PST, we aim to determine if SSIPP is as effective as the structured psychotherapy intervention PST at achieving these outcomes. Data from this study will help inform the design of a future large, multi-center RCT. OBJECTIVES Objective 1: To determine if it is feasible to conduct an RCT of telephone SSIPP in comparison to PST delivered to community-dwelling seniors during the current constraints imposed by COVID-19 and the need for telephone delivery of these services. Objective 2: To determine the extent of change in self-rated depression, anxiety, isolation and resilience measures in a telephone delivered SSIPP as compared to telephone delivered PST and wait list control among community dwelling seniors. HYPOTHESES Hypothesis 1: It will be feasible to conduct an RCT of telephone SSIPP in comparison to telephone PST and a wait list control, under the current constraints imposed by COVID-19 and the need for telephone delivery of these services. Hypothesis 2: It will be possible to collect effect size estimates of SSIPP compared to PST and a wait list control on symptoms of depression, anxiety, isolation and resilience in community dwelling seniors. STUDY DESIGN This study will be open label, randomized, controlled trial comparing 12-week telephone delivered SSIPP and PST in a total of 45 participants, randomized in a 1:1:1 ratio to one of three groups. The three study groups that participants could be randomized to, include SSIPP, PST, or a waitlist control (WLC). The WLC participants will self-select participation in either SSIPP or PST at the end of the 12-week waiting period. They will not complete study assessments following week 12. This study will plan to enroll n=45 with 15 participants randomized to each of the three groups. Participants will be asked to complete brief surveys, online in REDCap, or over the phone with a Research Assistant at weeks 0 and 12 of the study. REDCap will be used to achieve randomization and its concealment. Statistical analysts will be blinded to group allocation during data analysis. RECRUITMENT Participants will include community-dwelling seniors (n=45) recruited from the Division of Geriatric Psychiatry at Parkwood Institute and from the Geriatric Mental Health Program at London Health Sciences Center, both located in London, Ontario. Participants to these two programs receive referrals from family doctors serving the city of London and surrounding Middlesex County. The study will recruit via existing relationships and referrals established by the study PI and co-investigator. STATISTICAL ANALYSIS PLAN Primary outcome measures will be calculated using rates, percentages and costs. For exploratory purposes, the secondary outcome measures will be subject to the following analyses. A Multivariate Analysis of Variance (MANOVA) will be conducted to detect differences between the two interventions, i.e. SSIPP and PST as the independent variables and scores on GAD-7, PHQ-9, and CD-RISC-10 scale as the dependent variables. Multivariate F value (Wilks' λ or Hotelling's trace or Pillai's trace) will be used with a statistical significance set at p < 0.05. Demographic measures will be described using either calculations of means or percentage as required. As there is no consensus or current evidence recommending an appropriate sample size for feasibility studies, it is advised that feasibility study samples sizes not be attempted a priori. Pilot studies investigating the comparable psychotherapies cognitive behavioural therapy (CBT) and mindfulness-based cognitive therapy (MCBT) were able to demonstrate reductions in self-reported anxiety and depression with a sample size of n=52 and n=30, respectively. Given these effect sizes, the desired sample size is n=45. Attrition and retention rates will be calculated as feasibility measures as part of this pilot study to help inform required sample size for a future large, multi-center RCT. IBM SPSS ® (v26) will be used for the conduction of data analysis. Contingent on final sample size, either the Kolmogorov-Smirnov or the Shapiro-Wilk test will be used to assess normality of the data. The Expectation-Maximization (EM) algorithm will be used to account for missing data. Analysis will first be carried out using an Intent to Treat (ITT) approach, followed by per protocol (PP) analyses for the participants who completed the study only. The differences in anxiety, depression, and resiliency outcomes between the groups at week 0 and week 12 will be analyzed using a repeated MANOVA test, in both ITT and PP analysis groups. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |